BioAge Stock Advances 14% On Novartis Research Collaboration

Dow Jones12-18

By Katherine Hamilton

BioAge Labs shares rose Wednesday after it said it entered into a research collaboration with the Swiss biopharmaceutical company Novartis, which could earn BioAge up to $550 million.

Shares climbed 14% to $4.67, helping to regain some of the 76% loss BioAge experienced on Dec. 6 after it said it was discontinuing a phase-two trial for its obesity treatment.

The Richmond, Calif.-based biopharmaceutical company will collaborate on a multi-year research project with Novartis investigating what drives aging-related diseases and the role of physical exercise in longevity. It combines BioAge's human longevity datasets with Novartis's specialty in exercise biology, BioAge said.

Under the terms of the agreement, BioAge will receive upfront research funding and payments of up to $20 million, and up to $530 million in future research, development and commercial milestones. BioAge and Novartis both have the right to advance novel targets discovered during the collaboration.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 18, 2024 10:21 ET (15:21 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492187659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492187659","market":"hk","top_or_hot":-1,"title":"BioAge Stock Advances 14% On Novartis Research Collaboration","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  BioAge Labs shares rose Wednesday after it said it entered into a research collaboration with the Swiss biopharmaceutical company Novartis, which could earn BioAge up to $550 million. \n</p>\n<p>\n  Shares climbed 14% to $4.67, helping to regain some of the 76% loss BioAge experienced on Dec. 6 after it said it was discontinuing a phase-two trial for its obesity treatment. \n</p>\n<p>\n  The Richmond, Calif.-based biopharmaceutical company will collaborate on a multi-year research project with Novartis investigating what drives aging-related diseases and the role of physical exercise in longevity. It combines BioAge's human longevity datasets with Novartis's specialty in exercise biology, BioAge said. \n</p>\n<p>\n  Under the terms of the agreement, BioAge will receive upfront research funding and payments of up to $20 million, and up to $530 million in future research, development and commercial milestones. BioAge and Novartis both have the right to advance novel targets discovered during the collaboration. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 10:21 ET (15:21 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge Stock Advances 14% On Novartis Research Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge Stock Advances 14% On Novartis Research Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Katherine Hamilton \n\n\n  BioAge Labs shares rose Wednesday after it said it entered into a research collaboration with the Swiss biopharmaceutical company Novartis, which could earn BioAge up to $...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4578","symbol_name":"CAR-T","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492187659","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492187659","pubTimestamp":1734535260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BioAge Labs shares rose Wednesday after it said it entered into a research collaboration with the Swiss biopharmaceutical company Novartis, which could earn BioAge up to $550 million.Shares climbed 14% to $4.67, helping to regain some of the 76% loss BioAge experienced on Dec. 6 after it said it was discontinuing a phase-two trial for its obesity treatment.The Richmond, Calif.-based biopharmaceutical company will collaborate on a multi-year research project with Novartis investigating what drives aging-related diseases and the role of physical exercise in longevity. It combines BioAge's human longevity datasets with Novartis's specialty in exercise biology, BioAge said.Under the terms of the agreement, BioAge will receive upfront research funding and payments of up to $20 million, and up to $530 million in future research, development and commercial milestones. BioAge and Novartis both have the right to advance novel targets discovered during the collaboration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4578":"CAR-T","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","NVS":"诺华","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4007":"制药","BK4532":"文艺复兴科技持仓","BIOA":"BioAge Labs Inc."},"translate_title":"诺华研究合作推动BioAge股价上涨14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":0.9,"NVS":0.9},"content_text":"By Katherine Hamilton \n\n\n  BioAge Labs shares rose Wednesday after it said it entered into a research collaboration with the Swiss biopharmaceutical company Novartis, which could earn BioAge up to $550 million. \n\n\n  Shares climbed 14% to $4.67, helping to regain some of the 76% loss BioAge experienced on Dec. 6 after it said it was discontinuing a phase-two trial for its obesity treatment. \n\n\n  The Richmond, Calif.-based biopharmaceutical company will collaborate on a multi-year research project with Novartis investigating what drives aging-related diseases and the role of physical exercise in longevity. It combines BioAge's human longevity datasets with Novartis's specialty in exercise biology, BioAge said. \n\n\n  Under the terms of the agreement, BioAge will receive upfront research funding and payments of up to $20 million, and up to $530 million in future research, development and commercial milestones. BioAge and Novartis both have the right to advance novel targets discovered during the collaboration. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 10:21 ET (15:21 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492187659"}